ClinicalTrials.gg
TerminatedNCT03690869Updated Apr 8, 2025Results posted

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

A Phase 1/2 interventional study of cemiplimab (monotherapy) and cemiplimab (maintenance) in Relapsed Solid Tumor, Refractory Solid Tumor and Relapsed Central Nervous System Tumor, sponsored by Regeneron Pharmaceuticals. Terminated at 20 sites in United States. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Primary conditionDiffuse Intrinsic Pontine GliomaRegistry: Central Nervous System NeoplasmsReclassifiedWhy we changed it
Registry
Central Nervous System Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diffuse Intrinsic Pontine Glioma
Why
  1. The study's listed conditions name Diffuse Intrinsic Pontine Glioma, a narrower term within Central Nervous System Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
Up to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States — 23 open to participants now, 34 under way, none of them phase 3. Diffuse Intrinsic Pontine Glioma · United States.

Enrollment
22nd of 82
57 · median 30
Started
2018
with 8 others
Phase 1/2
17 of 88
4 open now
Registered
46th of 88
by date

Among the 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States, this one is the 22nd largest by enrollment of the 82 interventional ones that give a count, is one of 9 that started in 2018, is one of 17 in phase 1/2, and was the 46th registered.

Diffuse Intrinsic Pontine Glioma

119 studies on the registry are indexed under Diffuse Intrinsic Pontine Glioma; 38 are open to participants now.

Browse Diffuse Intrinsic Pontine Glioma studies →

Open to participants now

23 of the 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Diffuse Intrinsic Pontine Glioma studies recruiting now, 3 (11%) set no upper age limit and 25 (89%) stop at 75 or younger; 27 take children under 18; 2 take healthy volunteers.

This study: Up to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States, or all of them as a file.
02

Study summary

Phase 1:

  • To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors
  • To characterize the pharmacokinetics (PK) of REGN2810 given in children with recurrent or refractory solid or CNS tumors

Phase 2 (Efficacy Phase):

  • To confirm the safety and anticipated RP2D of REGN2810 to be given concomitantly with conventionally fractionated or hypofractionated radiation among patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
  • To confirm the safety and anticipated RP2D of REGN2810 given concomitantly with conventionally fractionated or hypofractionated radiation among patients with newly diagnosed high-grade glioma (HGG)
  • To confirm the safety and anticipated RP2D of REGN2810 given concomitantly with re-irradiation in patients with recurrent HGG
  • To assess PK of REGN2810 in pediatric patients with newly diagnosed DIPG, newly diagnosed HGG, or recurrent HGG when given in combination with radiation
  • To assess anti-tumor activity of REGN2810 in combination with radiation in improving overall survival at 12 months (OS12) among patients with newly diagnosed DIPG
  • To assess anti-tumor activity of REGN2810 in combination with radiation in improving progression-free survival at 12 months (PFS12) among patients with newly diagnosed HGG
  • To assess anti-tumor activity of REGN2810 in combination with radiation in improving overall survival at OS12 among patients with recurrent HGG
03

Conditions studied

  • Relapsed Solid Tumor
  • Refractory Solid Tumor
  • Relapsed Central Nervous System Tumor
  • Refractory Central Nervous System Tumor
  • Diffuse Intrinsic Pontine Glioma
  • High Grade Glioma

Keywords

  • Newly Diagnosed
  • Recurrent
  • Refractory
04

In context

Diffuse Intrinsic Pontine Glioma Reclassified

119 studies on the registry are indexed under Diffuse Intrinsic Pontine Glioma; 38 are open to participants now.

This study's enrollment of 57 is above the median of 30 across 109 interventional studies indexed under Diffuse Intrinsic Pontine Glioma.

Browse Diffuse Intrinsic Pontine Glioma studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Compared within Diffuse Intrinsic Pontine Glioma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Central Nervous System Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age 0 to \<18 years of age (Phase 1)
  2. Age ≥3 and ≤25 years of age (Efficacy Phase)
  3. performance status ≥50 (patients >16 years) or Lansky performance status ≥50 (patients ≤ 16 years)
  4. >8 weeks
  5. Adequate Bone Marrow Function
  6. Adequate Renal Function
  7. Adequate Liver Function
  8. Adequate Neurologic Function

Key Exclusion Criteria:

  1. Patients with bulky disease of the CNS causing Uncal herniation or symptomatic midline shift, significant, symptomatic mass effect, or uncontrolled neurological symptoms such as seizures or altered mental status
  2. Patients with metastatic spine disease and gliomatosis as documented by diffuse involvement of >2 lobes
  3. Patients who are receiving any other anticancer agent(s)
  4. Patients on greater than dexamethasone 0.1 mg/kg/day (maximum 4 mg/day) or equivalent dose in alternate , or actively undergoing corticosteroid dose escalation in the last 7 days
  5. Patients with a history of stem cell transplant
  6. Prior treatment with an agent that blocks the /PD-L1/PD-L2 pathway

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Phase 1

    Patients in both the Solid Tumor Cohort and the CNS Cohort will receive cemiplimab monotherapy. Each Cohort will have 2 subgroups by age (0 to \<12 years, 12 to \<18 years).

    Drug: cemiplimab (monotherapy)

  • Experimental
    Efficacy with Newly Diagnosed DIPG

    ≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy

    Drug: cemiplimab (maintenance) · Radiation: Conventional or hypofractionated

  • Experimental
    Efficacy with Newly Diagnosed HGG

    ≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy

    Drug: cemiplimab (maintenance) · Radiation: Conventional or hypofractionated

  • Experimental
    Efficacy with Recurrent HGG

    ≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy

    Drug: cemiplimab (maintenance) · Radiation: Re-irradiation

Interventions

  • To be administered intravenously as monotherapy in Phase 1

    Also known as: REGN2810, Libtayo

  • To be administered intravenously in combination with radiation and then used as maintenance therapy

    Also known as: REGN2810, Libtayo

  • RadiationConventional or hypofractionated

    Combined with cemiplimab IV administration

  • RadiationRe-irradiation

    Combined with cemiplimab IV administration

07

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent Adverse Events (TEAEs)

    TEAEs are AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occur during the post-treatment period but prior to initiation of other anticancer therapy. Number of TEAEs reported.

    Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)

  2. Number of Severe (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3/4/5) TEAEs

    NCI CTCAE version 4.0 was utilized for AE grading of severity: Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE). Number of NCI grade 3/4/5 Treatment-Emergent Adverse Events (AEs) reported

    Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)

  3. Number of Treatment-emergent Sponsor Identified Immune-related Adverse Events (irAEs)

    Number of sponsor-identified irAEs (all grades) reported.

    Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)

  4. Number of Severe (NCI CTCAE Grade 3/4/5) Treatment-emergent Sponsor Identified irAEs

    Number of severe treatment-emergent sponsor-identified irAEs reported.

    Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)

  5. Number of Treatment-emergent AEs of Special Interest (AESI)

    AEs of special interest (AESI) are AEs required to be monitored, documented, and managed in a pre-specified manner as described in the protocol. Number of treatment-emergent AESI reported.

    Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)

  6. Number of NCI Grade 3/4/5 Treatment-emergent AESI

    Number of NCI grade 3/4/5 treatment-emergent AESI reported

    Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)

  7. Number of Participants With Any TEAE Resulting in Death

    Number of participants with any TEAE resulting in death reported

    Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)

  8. Number of Participants With at Least One Lab Abnormality (NCI-CTCAE All Grades) in Hematology, Electrolytes, Liver, Chemistry

    Number of participants with new or worsened laboratory abnormalities (NCI-CTCAE All Grades) reported in Hematology, Electrolytes, Liver, Chemistry; Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE).

    Time frame: Up to 36 months

  9. Number of Participants Who Developed Dose Limiting Toxicities (DLTs) (Phase 1)

    Number of participants who developed dose limiting toxicities (DLTs) in phase 1 reported

    Time frame: Baseline to 28 days

  10. Number of Participants Who Developed DLTs (Efficacy Phase)

    Time frame: Up to 4 weeks post radiation therapy

  11. Elimination Half-life (t1/2) of Functional Cemiplimab (REGN2810) in Serum

    Time frame: Up to 24 months

  12. Trough Concentration (Ctrough) of Functional Cemiplimab (REGN2810) in Serum

    Ctrough (trough concentration) of functional cemiplimab in serum reported.

    Time frame: Up to Week 16

  13. Peak Concentration (Cmax) of Functional Cemiplimab (REGN2810) in Serum

    Cmax (peak concentration) of functional cemiplimab in serum reported.

    Time frame: Up to Week 16

  14. Area Under the Concentration-time Curve (AUC) of Functional Cemiplimab (REGN2810) in Serum

    Time frame: Up to 24 months

  15. Percentage of Progression-free Survival (PFS) at 12 Months for Participants With Newly Diagnosed HGG (ndHGG)

    PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined per Response Assessment in Neuro-Oncology (RANO)/Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria, or death due to any cause.

    Time frame: At 12 months

  16. Percentage of Overall Survival (OS) at 12 Months for Participants With ndDIPG and Recurrent HGG (rHGG)

    OS was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last date that participant was documented to be alive. 95% CI is based on Kaplan-Meier method.

    Time frame: Up to 12 months

Secondary outcomes

  1. Objective Response Rate (ORR) for Participants Who Have a Confirmed Complete Response (CR) or Partial Response (PR)

    ORR was defined as the percentage of participants who have a confirmed complete response (CR) or partial response (PR), as determined per standard criteria between the date of first study treatment and the date of the first objectively documented progression or the date of receiving another anti-cancer systemic therapy, whichever came first. Clopper-Person exact confidence interval

    Time frame: Approximately 24 months

  2. Number of Participants With Anti-REGN2810 Antibodies (ADA)

    ADA status classified as: Positive; Pre-existing (baseline \[BL\] sample positive \& all post BL ADA titers reported as \< 9-fold BL titer value); Negative (all samples negative); ADA positive: Treatment-boosted (positive result at BL with ≥1 post BL titer result ≥9-fold BL titer value); Treatment-emergent (TE) (negative result or missing result at BL with ≥1 positive post BL result); TE: Persistent (positive result detected in ≥2 consecutive post BL samples separated by ≥ a 12/16-week post BL period with no ADA-negative results in-between, regardless of any missing samples; Indeterminate (positive result in last collection, regardless of any missing samples); Transient (not persistent or indeterminate, regardless of any missing samples)

    Time frame: 1st follow-up visit, approximately 25 months

08

Results

Posted Oct 9, 2024
Limitations and caveats
As all efficacy cohorts for this study have now been closed due to the futility criteria, Regeneron as Sponsor in collaboration with PNOC made a decision to close the study to further enrollment.

Participant flow

Participant flow — Overall Study
MilestoneSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Started35395651218
Completed0000000100
Not completed35395651118
Withdrew: Adverse event0001000101
Withdrew: Death1114253203
Withdrew: Lost to follow-up0010000000
Withdrew: Other treatment1112312703
Withdrew: Physician decision0100000000
Withdrew: Progressive disease1201000011
Withdrew: Subject decision0001000100

Outcome measures

PrimaryNumber of Treatment-emergent Adverse Events (TEAEs)

TEAEs are AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occur during the post-treatment period but prior to initiation of other anticancer therapy. Number of TEAEs reported.

Time frame:
From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Reported as:
Number · Events
Number of Treatment-emergent Adverse Events (TEAEs)
EventsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Number of Treatment-emergent Adverse Events (TEAEs)194224564910810222228175
PrimaryNumber of Severe (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3/4/5) TEAEs

NCI CTCAE version 4.0 was utilized for AE grading of severity: Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE). Number of NCI grade 3/4/5 Treatment-Emergent Adverse Events (AEs) reported

Time frame:
From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Reported as:
Number · Events
Number of Severe (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3/4/5) TEAEs
EventsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Number of Severe (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3/4/5) TEAEs3509425819416
PrimaryNumber of Treatment-emergent Sponsor Identified Immune-related Adverse Events (irAEs)

Number of sponsor-identified irAEs (all grades) reported.

Time frame:
From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Reported as:
Number · Events
Number of Treatment-emergent Sponsor Identified Immune-related Adverse Events (irAEs)
EventsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Number of Treatment-emergent Sponsor Identified Immune-related Adverse Events (irAEs)0100025909
PrimaryNumber of Severe (NCI CTCAE Grade 3/4/5) Treatment-emergent Sponsor Identified irAEs

Number of severe treatment-emergent sponsor-identified irAEs reported.

Time frame:
From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Reported as:
Number · Events
Number of Severe (NCI CTCAE Grade 3/4/5) Treatment-emergent Sponsor Identified irAEs
EventsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Number of Severe (NCI CTCAE Grade 3/4/5) Treatment-emergent Sponsor Identified irAEs0000003201
PrimaryNumber of Treatment-emergent AEs of Special Interest (AESI)

AEs of special interest (AESI) are AEs required to be monitored, documented, and managed in a pre-specified manner as described in the protocol. Number of treatment-emergent AESI reported.

Time frame:
From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Reported as:
Number · Events
Number of Treatment-emergent AEs of Special Interest (AESI)
EventsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Number of Treatment-emergent AEs of Special Interest (AESI)0000152408
PrimaryNumber of NCI Grade 3/4/5 Treatment-emergent AESI

Number of NCI grade 3/4/5 treatment-emergent AESI reported

Time frame:
From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Reported as:
Number · Events
Number of NCI Grade 3/4/5 Treatment-emergent AESI
EventsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Number of NCI Grade 3/4/5 Treatment-emergent AESI0000122406
PrimaryNumber of Participants With Any TEAE Resulting in Death

Number of participants with any TEAE resulting in death reported

Time frame:
From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Reported as:
Number · Participants
Number of Participants With Any TEAE Resulting in Death
ParticipantsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Number of Participants With Any TEAE Resulting in Death0000000000
PrimaryNumber of Participants With at Least One Lab Abnormality (NCI-CTCAE All Grades) in Hematology, Electrolytes, Liver, Chemistry

Number of participants with new or worsened laboratory abnormalities (NCI-CTCAE All Grades) reported in Hematology, Electrolytes, Liver, Chemistry; Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE).

Time frame:
Up to 36 months
Reported as:
Number · Participants
Number of Participants With at Least One Lab Abnormality (NCI-CTCAE All Grades) in Hematology, Electrolytes, Liver, Chemistry
ParticipantsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
≥ 1 lab abnormality (All Grades) Hematology34373641118
≥ 1 lab abnormality (All Grades) Electrolytes3305264917
≥ 1 lab abnormality (All Grades) Liver1205345715
≥ 1 lab abnormality (All Grades) Chemistry35364641017
PrimaryNumber of Participants Who Developed Dose Limiting Toxicities (DLTs) (Phase 1)

Number of participants who developed dose limiting toxicities (DLTs) in phase 1 reported

Time frame:
Baseline to 28 days
Reported as:
Number · Participants
Number of Participants Who Developed Dose Limiting Toxicities (DLTs) (Phase 1)
ParticipantsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kg
Number of Participants Who Developed Dose Limiting Toxicities (DLTs) (Phase 1)00000
PrimaryNumber of Participants Who Developed DLTs (Efficacy Phase)
Time frame:
Up to 4 weeks post radiation therapy
Reported as:
Number · Participants
Number of Participants Who Developed DLTs (Efficacy Phase)
ParticipantsCohort E Efficacy Phase ndDIPG (DLT AS)Cohort F Efficacy Phase ndDIPG (DLT AS)Cohort H Efficacy Phase ndHGG (DLT AS)Cohort I Efficacy Phase rHGG (DLT AS)Cohort J Efficacy Phase rHGG (DLT AS)
Number of Participants Who Developed DLTs (Efficacy Phase)11001
PrimaryElimination Half-life (t1/2) of Functional Cemiplimab (REGN2810) in Serum
Time frame:
Up to 24 months
Reported as:
Median · milligrams/Liter (mg/L)
Elimination Half-life (t1/2) of Functional Cemiplimab (REGN2810) in Serum
milligrams/Liter (mg/L)Cohort A Phase 1 ST 3mg/kg Q2W (PKAS)Cohort B Phase 1 ST 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS)Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS)Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS)Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS)Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS)Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS)
Elimination Half-life (t1/2) of Functional Cemiplimab (REGN2810) in SerumNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
PrimaryTrough Concentration (Ctrough) of Functional Cemiplimab (REGN2810) in Serum

Ctrough (trough concentration) of functional cemiplimab in serum reported.

Time frame:
Up to Week 16
Reported as:
Median · mg/L
Trough Concentration (Ctrough) of Functional Cemiplimab (REGN2810) in Serum
mg/LCohort A Phase 1 ST 3mg/kg Q2W (PKAS)Cohort B Phase 1 ST 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS)Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS)Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS)Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS)Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS)Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS)
Ctrough - after 1st dose16.7 (14.0 to 16.8)23.9 (21.1 to 27.2)33.8 (27.9 to 36.5)28.5 (19.6 to 42.2)48.3 (32.9 to 63.8)39.7 (33.9 to 41.9)26.0 (17.4 to 36.3)36.3 (25.2 to 178)35.8 (32.4 to 49.6)NA (38.5 to 38.5)
Ctrough - Week 16 (Cycle 4 Day 1) (4 weeks per cycle)NA (39.4 to 39.4)NA (78.6 to 78.6)—NA (66.1 to 66.1)NA (66.1 to 66.1)82.4 (65.7 to 104)94.3 (84.5 to 247)78.5 (57.0 to 134)122 (13.1 to 159)NA (70.0 to 70.0)
PrimaryPeak Concentration (Cmax) of Functional Cemiplimab (REGN2810) in Serum

Cmax (peak concentration) of functional cemiplimab in serum reported.

Time frame:
Up to Week 16
Reported as:
Median · mg/L
Peak Concentration (Cmax) of Functional Cemiplimab (REGN2810) in Serum
mg/LCohort A Phase 1 ST 3mg/kg Q2W (PKAS)Cohort B Phase 1 ST 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS)Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS)Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS)Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS)Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS)Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS)
Cmax - after 1st dose58.2 (52.0 to 86.9)73.5 (63.4 to 87.9)92.2 (87.9 to 101)68.3 (60.9 to 101)152 (76.0 to 202)95.1 (65.5 to 106)71.8 (6.41 to 88.0)88.8 (69.5 to 124)105 (93.7 to 130)NA (123 to 123)
Cmax -Week 16 (Cycle 4 Day 1) (4 weeks per cycle)NA (122 to 122)NA (136 to 136)NA (112 to 112)NA (112 to 112)NA (236 to 236)221 (164 to 256)165 (143 to 200)179 (119 to 234)209 (99.2 to 297)NA (225 to 225)
PrimaryArea Under the Concentration-time Curve (AUC) of Functional Cemiplimab (REGN2810) in Serum
Time frame:
Up to 24 months
Reported as:
Median · mg*hr/L
Area Under the Concentration-time Curve (AUC) of Functional Cemiplimab (REGN2810) in Serum
mg*hr/LCohort A Phase 1 ST 3mg/kg Q2W (PKAS)Cohort B Phase 1 ST 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS)Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS)Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS)Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS)Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS)Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS)Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS)
Area Under the Concentration-time Curve (AUC) of Functional Cemiplimab (REGN2810) in SerumNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
PrimaryPercentage of Progression-free Survival (PFS) at 12 Months for Participants With Newly Diagnosed HGG (ndHGG)

PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined per Response Assessment in Neuro-Oncology (RANO)/Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria, or death due to any cause.

Time frame:
At 12 months
Reported as:
Number · Percentage of Participants
Percentage of Progression-free Survival (PFS) at 12 Months for Participants With Newly Diagnosed HGG (ndHGG)
Percentage of ParticipantsndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy
Percentage of Progression-free Survival (PFS) at 12 Months for Participants With Newly Diagnosed HGG (ndHGG)22.2 (3.4 to 51.3)
PrimaryPercentage of Overall Survival (OS) at 12 Months for Participants With ndDIPG and Recurrent HGG (rHGG)

OS was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last date that participant was documented to be alive. 95% CI is based on Kaplan-Meier method.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of Participants
Percentage of Overall Survival (OS) at 12 Months for Participants With ndDIPG and Recurrent HGG (rHGG)
Percentage of ParticipantsndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Percentage of Overall Survival (OS) at 12 Months for Participants With ndDIPG and Recurrent HGG (rHGG)0.0 (NA to NA)40.0 (5.2 to 75.3)0.0 (NA to NA)35.7 (5.2 to 69.9)
SecondaryObjective Response Rate (ORR) for Participants Who Have a Confirmed Complete Response (CR) or Partial Response (PR)

ORR was defined as the percentage of participants who have a confirmed complete response (CR) or partial response (PR), as determined per standard criteria between the date of first study treatment and the date of the first objectively documented progression or the date of receiving another anti-cancer systemic therapy, whichever came first. Clopper-Person exact confidence interval

Time frame:
Approximately 24 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) for Participants Who Have a Confirmed Complete Response (CR) or Partial Response (PR)
Percentage of ParticipantsSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgNewly Diagnosed HGG (ndHGG) (Efficacy Phase)CNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Objective Response Rate (ORR) for Participants Who Have a Confirmed Complete Response (CR) or Partial Response (PR)0 (0.0 to 70.8)0 (0.0 to 52.2)0 (0.0 to 70.8)0 (0.0 to 33.6)0 (0.0 to 52.2)0 (0.0 to 45.9)0 (0.0 to 52.2)8.3 (0.2 to 38.5)0 (0.0 to 97.5)0 (0.0 to 36.9)
SecondaryNumber of Participants With Anti-REGN2810 Antibodies (ADA)

ADA status classified as: Positive; Pre-existing (baseline \[BL\] sample positive \& all post BL ADA titers reported as \< 9-fold BL titer value); Negative (all samples negative); ADA positive: Treatment-boosted (positive result at BL with ≥1 post BL titer result ≥9-fold BL titer value); Treatment-emergent (TE) (negative result or missing result at BL with ≥1 positive post BL result); TE: Persistent (positive result detected in ≥2 consecutive post BL samples separated by ≥ a 12/16-week post BL period with no ADA-negative results in-between, regardless of any missing samples; Indeterminate (positive result in last collection, regardless of any missing samples); Transient (not persistent or indeterminate, regardless of any missing samples)

Time frame:
1st follow-up visit, approximately 25 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-REGN2810 Antibodies (ADA)
ParticipantsPhase 1: 3mg/kg Q2W (AAS)Phase 1: 4.5mg/kg Q2W (AAS)Efficacy Phase: 3mg/kg Q2W (AAS)Efficacy Phase: 4.5mg/kg Q2W (AAS)
Negative165176
Pre-existing immunoreactivity0010
Treatment-emergent (TE) response0011

Adverse events

Collected over From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOLID TUMOR < 12 yr REGN2810 3mg/kg2/3 (66.7%)0/3 (0%)3/3 (100%)
SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg4/5 (80%)0/5 (0%)5/5 (100%)
CNS TUMOR <12 yr REGN2810 3mg/kg2/3 (66.7%)0/3 (0%)2/3 (66.7%)
CNS TUMOR <12 yr REGN2810 4.5mg/kg8/9 (88.9%)3/9 (33.3%)8/9 (88.9%)
CNS TUMOR 12 to <18 yr REGN2810 3mg/kg3/5 (60%)0/5 (0%)4/5 (80%)
ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy6/6 (100%)3/6 (50%)6/6 (100%)
ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy4/5 (80%)3/5 (60%)5/5 (100%)
ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy7/12 (58.3%)7/12 (58.3%)12/12 (100%)
rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation1/1 (100%)0/1 (0%)1/1 (100%)
rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation5/8 (62.5%)5/8 (62.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
Tumour pseudoprogressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/50/30/90/52/60/51/120/10/8
Alanine aminotransferase increasedInvestigations0/30/50/30/90/50/61/51/120/10/8
ArthralgiaMusculoskeletal and connective tissue disorders0/30/50/30/90/50/61/50/120/11/8
HeadacheNervous system disorders0/30/50/30/90/50/61/51/120/11/8
HydrocephalusNervous system disorders0/30/50/30/90/50/61/50/120/11/8
HypoxiaRespiratory, thoracic and mediastinal disorders0/30/50/30/90/51/60/50/120/10/8
Device related infectionInfections and infestations0/30/50/30/90/51/60/50/120/10/8
ConstipationGastrointestinal disorders0/30/50/30/90/51/60/50/120/10/8
Wound dehiscenceInjury, poisoning and procedural complications0/30/50/30/90/51/60/50/120/10/8
Weight decreasedInvestigations0/30/50/30/90/51/60/50/120/10/8
Most frequent other events
Showing 10 of 209
Most frequent other events
EventSOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation
HypokalaemiaMetabolism and nutrition disorders1/30/50/33/91/50/62/52/121/11/8
HypophosphataemiaMetabolism and nutrition disorders1/30/50/31/91/51/60/54/121/11/8
HyperglycaemiaMetabolism and nutrition disorders0/30/50/30/90/50/62/52/121/11/8
HypoalbuminaemiaMetabolism and nutrition disorders0/31/50/30/90/50/61/51/121/11/8
HypocalcaemiaMetabolism and nutrition disorders0/30/50/30/90/50/61/51/121/12/8
HypoglycaemiaMetabolism and nutrition disorders0/30/50/30/90/50/61/50/121/10/8
HyponatraemiaMetabolism and nutrition disorders0/30/50/30/90/51/60/52/121/10/8
Abdominal pain upperGastrointestinal disorders0/30/50/30/90/50/60/51/121/10/8
FatigueGeneral disorders1/31/51/32/94/51/62/56/121/16/8
PyrexiaGeneral disorders1/31/51/30/91/51/61/53/121/11/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)SOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-IrradiationTotal
Mean7.0 ± 5.2913.4 ± 1.957.7 ± 1.537.1 ± 2.2615.0 ± 1.004.8 ± 1.8315.4 ± 2.4116.4 ± 3.638.0 ± 016.3 ± 3.0112.1 ± 5.23
Sex: Female, Male
Sex: Female, Male(Participants)SOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-IrradiationTotal
Female121424441225
Male232532180632
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-IrradiationTotal
Hispanic or Latino030233151321
Not Hispanic or Latino323721460533
Unknown or Not Reported00000201003
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOLID TUMOR < 12 yr REGN2810 3mg/kgSOLID TUMOR 12 to <18 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 3mg/kgCNS TUMOR <12 yr REGN2810 4.5mg/kgCNS TUMOR 12 to <18 yr REGN2810 3mg/kgndDIPG <12 yr REGN2810 4.5mg/kg + RadiotherapyndDIPG >=12 yr REGN2810 3mg/kg + RadiotherapyndHGG >=12 yr REGN2810 3mg/kg + RadiotherapyrHGG <12 yr REGN2810 4.5mg/kg + Re-IrradiationrHGG >= 12 yr REGN2810 3mg/kg + Re-IrradiationTotal
White3335324121440
Black or African American01010110026
Asian00000000011
American Indian or Alaska Native00010100002
Native Hawaiian or Other Pacific Islander00010000001
Other00000100001
Unknown00012000014
Not reported01000100002
09

Study locations

20 sites
  • Children's Hospital Los Angeles (CHLA)
    Los Angeles, California 90054, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • UCSF Benioff Children's Hospital
    San Francisco, California 94158, United States
  • Children's National Health System (Children's National Medical Center)
    Washington, District of Columbia 20010, United States
  • University of Florida- Neurosurgery
    Gainesville, Florida 32610, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Johns Hopkins - Pediatric Oncology
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute/ Boston Children's Hospital
    Boston, Massachusetts 02215, United States
  • C. S. Mott/University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • University of Minnesota / Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health & Science University (OHSU) - Doernbecher Children's Hospital
    Portland, Oregon 97239, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Texas Children's Cancer & Hematology Centers Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in May 2023, 55 months.

Results were first posted in Oct 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Oct 1, 2018
StartActual
Sep 24, 2018
Primary completionActual
May 10, 2023
CompletionActual
May 10, 2023
Results first posted
Oct 9, 2024
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03690869
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Sep 24, 2018
Primary completion
May 10, 2023
Completion
May 10, 2023
Results posted
Oct 9, 2024
Last update
Apr 8, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion